AI-Ready Commerce Platform for a National DME Retailer
E-commerce / Healthcare / Durable Medical Equipment
AI-Ready Commerce Platform for a National DME Retailer
For pharmaceutical companies, expanding a therapeutic program beyond its original indication can unlock significant value, but identifying the right opportunities requires navigating vast amounts of genetic, clinical, and translational data.This case study explores how a pharmaceutical company leveraged AI to systematically evaluate new disease indications for TRPV1-targeted therapies and support strategic portfolio expansion.
Nextigent AI developed an Indication Discovery and Expansion Platform that combined biomedical intelligence, machine learning, and literature analysis to identify new therapeutic opportunities for TRPV1 modulation.
- Healthcare
- 4 months
- 6 specialists
5
new disease indications identified
2
indications demonstrated favorable clinical pathways and low competitive pressure
↑
Accelerated portfolio expansion decision-making
Project Scope
The project included aggregating biomedical and clinical datasets, developing indication-ranking models, deploying AI-assisted literature mining capabilities, and creating visualization dashboards for research and strategy teams.The platform was designed to support ongoing indication discovery efforts across future target programs.
Tech Stack
- Python
- TensorFlow
- Vertex AI
- Spotfire
Data sources
- GWAS Catalog
- OpenTargets
- ClinicalTrials.gov
- Pharmaproject
- PubMed
The Client
The client is a pharmaceutical company developing therapies targeting the TRPV1 receptor.The company wanted to identify additional disease indications where TRPV1 modulation could provide therapeutic benefit and support long-term portfolio growth.
Business Requirements
- Identify new disease indications supported by scientific evidence
- Evaluate biological plausibility and translational potential
- Reduce time spent on manual indication research
- Support strategic R&D investment decisions
- Create a repeatable framework for indication expansion across future programs
The Problem
Researchers and business teams lacked a systematic process for evaluating new therapeutic opportunities linked to TRPV1.Existing approaches relied heavily on manual literature reviews and fragmented analyses of clinical and genetic data, resulting in slow, inconsistent indication prioritization.
The Challenges
- Integrating data from multiple scientific and clinical sources
- Evaluating both biological relevance and commercial attractiveness
- Identifying emerging opportunities before competitors
- Providing explainable outputs for both scientific and business stakeholders
Problems Revealed
The project revealed that valuable evidence supporting additional indications existed across multiple datasets but was not connected through a unified decision-making framework.As a result, promising therapeutic opportunities were difficult to compare and prioritize objectively.
The Solution
Nextigent AI implemented the Indication Discovery and Expansion AI Platform to evaluate target-disease relationships at scale.The platform combined genetic associations, translational evidence, clinical pipeline data, and market intelligence into a unified ranking system. Machine learning models assessed biological plausibility, while LLM-assisted literature mining uncovered emerging scientific signals and supporting evidence.Interactive dashboards enabled researchers and portfolio managers to visualize indication rankings, compare opportunities, and evaluate potential clinical success probabilities.The solution was deployed within a secure cloud environment integrated with the client’s internal research ecosystem.
Achievements
- Identified 5 new disease indications with measurable scientific support
- Highlighted 2 opportunities with favorable development pathways and limited competition
- Improved confidence in portfolio diversification decisions
- Accelerated evaluation of new therapeutic opportunities
The platform transformed indication expansion from an exploratory exercise into a structured, AI-driven process.
Future Plans
The client plans to apply the platform to additional therapeutic targets across pain, inflammation, and neurological disorders.Future enhancements include predictive modeling for indication success rates and automated competitive intelligence monitoring.
Ready to see how enterprise-grade security can accelerate your AI initiatives?
Schedule a Technical Security Briefing